Project Grant R21NS144519
- This Project Grant award, with a total funding amount of $909,090, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The award supports research aimed at developing a therapeutic strategy to treat prion diseases, a rare class of neurodegenerative disorders. Specifically, the grant will fund investigations into a small molecule compound, A5,...
- This federal Project Grant award of $869,478 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research into the cellular and molecular mechanisms underlying hereditary prion diseases. The awardee, Trustees of Boston University, is using cutting-edge induced pluripotent stem cell (iPSC) approaches to model and study Creutzfeldt-Jakob disease (CJD) pathology in...
- This federal Project Grant award of $429,000.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to investigate the pathogenic mechanisms underlying Creutzfeldt-Jakob disease (CJD), a rapidly progressive dementia. The award will support research at the University of Texas Health Science Center at Houston to: 1) explore the structural differences between pathogenic and...
- This federal Project Grant award of $386,650 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at Midwestern University in Glendale, Arizona to identify the molecular target and cellular mechanisms by which the novel compound elacridar exerts anti-prion effects. The research aims to further explore the potential application of elacridar to treat other...
- The National Science Foundation Division of Environmental Biology awarded a $358,777 Project Grant to the College of William and Mary under the Biological Sciences federal grant program (CFDA 47.074) to fund collaborative research from July 2022 to June 2026. The research aims to advance understanding of how natural selection impacts prions, which are protein-based infectious agents that can cause diseases like mad cow disease, at multiple levels from molecules to biological communities....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $628,726 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Priogen Corp to develop a microfluidic device for the rapid detection of misfolded prion proteins associated with transmissible spongiform encephalopathies (TSEs). The 2-month project aims to refine Priogen's "Micro-QUIC" device, which leverages microfluidic channels and acoustic wave technology, to distinguish...
- This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...
- The National Science Foundation awarded a $1,027,074 Project Grant to Stanford University under the Biological Sciences federal grant program (CFDA 47.074) for work spanning July 15, 2022 to June 30, 2026. The award will support research examining how natural selection impacts prions, which are proteins that can replicate across generations and in some cases cause disease, at multiple levels from molecules to biological communities. Specifically, the grantee will conduct an experimental...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,830,581 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program to The Johns Hopkins University. The grant supports in-depth characterization of the mechanism of action of a new macrocycle molecule called RAPIREON, which selectively activates the nuclease activity of the IRE1 protein in the unfolded protein response (UPR) pathway....
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,025,015 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Scintillon Institute in California. The grant, awarded on August 11, 2025, supports the development of a next-generation preclinical model of NeuroHIV that better recapitulates the neuro-immune-vascular system interactions in the context of antiretroviral therapy-mediated HIV suppression....
This federal Project Grant award for $481,250.00, awarded on August 1, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the use of potent prion protein (PrP)-lowering reagents to treat prion disease. The key research objectives are to: The awardee, The Broad Institute, Inc., will conduct this research to inform the design of future clinical trials for prion disease treatments. The findings are expected to delineate the requirements for efficacy against recalcitrant prion strains and quantify the threshold of PrP lowering needed to achieve prion clearance.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $481.3k | 7/29/25 |